Camber (Camber)
Fesoterodine Fumarate Tablet, Film Coated, Extended Release
Product Images NDC 31722-034
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Fesoterodine Fumarate (NDC 31722-034). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Camberlogo (Camberlogo)
Fesoterodine-4mg-30s (Fesoterodine 4mg 30s)
Label for Fesoterodine Fumarate Extended-release Tablets 4 mg by Camber Pharmaceuticals, Inc. The label displays the product name, dosage strength (4 mg), and package size of 30 tablets. It includes storage instructions, a barcode, manufacturing details by Annora Pharma Pvt. Ltd., and contact information. The label specifies the product is Rx only.*
Fesoterodine-8mg-30s (Fesoterodine 8mg 30s)
Fesoterodine Fumarate extended-release tablets, 8 mg strength, film coated. The label shows a 30-tablet count package, NDC 31722-034-30, by Camber Pharmaceuticals, Inc. The label includes storage instructions, dosage advisory to swallow whole, contact number, manufacturer details, and a barcode.*
Figure-1 (Figure 1)
A line graph titled 'Change in Number of Micturitions per 24 h (Study 1)' showing mean change from baseline in number of micturitions over 12 weeks. It compares placebo, Fesoterodine fumarate extended-release tablets 4 mg, and 8 mg, with data points for each group plotted at intervals up to 12 weeks. The graph shows a decrease for all groups, with greater reductions for the 4 mg and 8 mg doses compared to placebo.*
Figure-2 (Figure 2)
A line graph titled 'Change in Urge Incontinence Episodes per 24 h (Study 1)' displaying mean change from baseline in urge incontinence episodes over 12 weeks. The graph compares placebo, Fesoterodine fumarate extended-release tablets 4 mg, and 8 mg, showing data points and trendlines for each group over time.*
Figure-3 (Figure 3)
A line graph titled 'Change in Number of Micturitions per 24 h (Study 2)' showing mean changes from baseline in micturitions over 12 weeks. The x-axis is labeled Weeks (from 0 to 12) and the y-axis is labeled Mean Change from baseline (number of micturitions per 24 h). Three lines represent placebo, Fesoterodine fumarate 4 mg extended-release tablets, and Fesoterodine fumarate 8 mg extended-release tablets. Both Fesoterodine dose groups show a greater decrease in number of micturitions compared to placebo throughout the study.*
Figure-4 (Figure 4)
A line graph depicting the mean change from baseline in urge incontinence episodes per 24 hours over 12 weeks in Study 2. It compares placebo, 4 mg fesoterodine fumarate extended-release tablets, and 8 mg fesoterodine fumarate extended-release tablets, showing decreasing episodes over time with both dosages compared to placebo.*
Structure (Structure)
Chemical structure of Fesoterodine fumarate, depicting the molecular arrangement of atoms and bonds for the active pharmaceutical ingredient.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
